AKYAAkoya Biosciences, Inc.

Nasdaq akoyabio.com


$ 2.40 $ 0.00 (0 %)    

Wednesday, 21-Aug-2024 15:59:56 EDT
QQQ $ 482.88 $ 2.24 (0.47 %)
DIA $ 408.91 $ 0.43 (0.11 %)
SPY $ 560.81 $ 1.92 (0.34 %)
TLT $ 98.72 $ 0.06 (0.06 %)
GLD $ 232.16 $ -0.31 (-0.13 %)
$ 2.41
$ 2.40 x 198
$ 2.41 x 200
-- - --
$ 1.88 - $ 6.31
68,879
na
119.1M
$ 1.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-04-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-07-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 03-14-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-11-2021 06-30-2021 10-Q
14 05-19-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 piper-sandler-maintains-overweight-on-akoya-biosciences-lowers-price-target-to-4

Piper Sandler analyst David Westenberg maintains Akoya Biosciences (NASDAQ:AKYA) with a Overweight and lowers the price targ...

 morgan-stanley-downgrades-akoya-biosciences-to-equal-weight-lowers-price-target-to-3

Morgan Stanley analyst Tejas Savant downgrades Akoya Biosciences (NASDAQ:AKYA) from Overweight to Equal-Weight and lowers th...

 btig-downgrades-akoya-biosciences-to-neutral

BTIG analyst Mark Massaro downgrades Akoya Biosciences (NASDAQ:AKYA) from Buy to Neutral.

 craig-hallum-maintains-buy-on-akoya-biosciences-lowers-price-target-to-7

Craig-Hallum analyst Bill Bonello maintains Akoya Biosciences (NASDAQ:AKYA) with a Buy and lowers the price target from $7.5...

 jp-morgan-downgrades-akoya-biosciences-to-neutral

JP Morgan analyst Rachel Vatnsdal downgrades Akoya Biosciences (NASDAQ:AKYA) from Overweight to Neutral.

 akoya-biosciences-q2-2024-gaap-eps-027-inline-sales-23164m-miss-23552m-estimate

Akoya Biosciences (NASDAQ:AKYA) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. The c...

 morgan-stanley-maintains-overweight-on-akoya-biosciences-lowers-price-target-to-4

Morgan Stanley analyst Tejas Savant maintains Akoya Biosciences (NASDAQ:AKYA) with a Overweight and lowers the price target ...

 canaccord-genuity-maintains-buy-on-akoya-biosciences-lowers-price-target-to-6

Canaccord Genuity analyst Kyle Mikson maintains Akoya Biosciences (NASDAQ:AKYA) with a Buy and lowers the price target from ...

 btig-maintains-buy-on-akoya-biosciences-lowers-price-target-to-6

BTIG analyst Mark Massaro maintains Akoya Biosciences (NASDAQ:AKYA) with a Buy and lowers the price target from $9 to $6.

 akoya-biosciences-cuts-fy24-revenue-forecast-from-114m-118m-to-104m-112m-est-115767m

Akoya is updating its revenue outlook for the full year 2024 while maintaining its commitment to achieving operating cash flow ...

 akoya-biosciences-q1-2024-adj-eps-039-misses-029-estimate-sales-18350m-miss-24281m-estimate

Akoya Biosciences (NASDAQ:AKYA) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $...

 akoya-biosciences-and-neracare-enter-exclusive-agreement-to-enable-personalized-therapy-selection-for-early-stage-melanoma-patients

Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of laboratory tests for ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION